Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16224068rdf:typepubmed:Citationlld:pubmed
pubmed-article:16224068lifeskim:mentionsumls-concept:C0024432lld:lifeskim
pubmed-article:16224068lifeskim:mentionsumls-concept:C0003009lld:lifeskim
pubmed-article:16224068lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:16224068lifeskim:mentionsumls-concept:C1148932lld:lifeskim
pubmed-article:16224068lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16224068lifeskim:mentionsumls-concept:C0920533lld:lifeskim
pubmed-article:16224068lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:16224068lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:16224068pubmed:issue9lld:pubmed
pubmed-article:16224068pubmed:dateCreated2005-10-28lld:pubmed
pubmed-article:16224068pubmed:abstractTextAngiotensin II (Ang II) is a powerful accelerator of atherosclerosis. Herein, we describe a novel transcription mechanism through which Ang II inhibits macrophage expression of the ATP-binding cassette transporter A1 (ABCA1), a key regulator of reverse cholesterol transport. We demonstrate that chronic Ang II infusion substantially promotes macrophage infiltration, foam cell formation, and atherosclerosis in low-density lipoprotein receptor-deficient mice and significantly reduces ABCA1 expression in peripheral macrophages. Administration of the Ang II type 1 receptor blocker valsartan inhibited Ang II-induced ABCA1 mRNA repression, macrophage cholesterol accumulation, and atherosclerosis. Ang II treatment reduced ABCA1 promoter activity of in vitro cultured mouse peritoneal macrophages, inducing fos-related antigen 2 (Fra2) protein binding to an ABCA1 promoter E-box motif, a site known to negatively regulate macrophage ABCA1 transcription. Valsartan pretreatment blocked Fra2 binding to the ABCA1 promoter, and Fra2 small interfering RNA pretreatment attenuated Ang II-mediated ABCA1 transcriptional inhibition, confirming the role of Fra2 in this process. This new evidence suggests that Ang II, a well-known proinflammatory and pro-oxidative factor, alters macrophage cholesterol homeostasis by repressing ABCA1 to promote foam cell formation and atherosclerosis.lld:pubmed
pubmed-article:16224068pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:languageenglld:pubmed
pubmed-article:16224068pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:citationSubsetIMlld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16224068pubmed:statusMEDLINElld:pubmed
pubmed-article:16224068pubmed:monthOctlld:pubmed
pubmed-article:16224068pubmed:issn1524-4571lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:VighB JBJlld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:DowW HWHlld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:HigakiJitsuoJlld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:TakataYasunor...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:HsuehWilla...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:LawRonald ERElld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:FishbeinMicha...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:BlaschkeFlori...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:CollinsAlan...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:TangiralaRaje...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:BruemmerDenni...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:LyonChristoph...lld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:DaleyWilliamWlld:pubmed
pubmed-article:16224068pubmed:authorpubmed-author:CaglayanEvren...lld:pubmed
pubmed-article:16224068pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16224068pubmed:day28lld:pubmed
pubmed-article:16224068pubmed:volume97lld:pubmed
pubmed-article:16224068pubmed:ownerNLMlld:pubmed
pubmed-article:16224068pubmed:authorsCompleteYlld:pubmed
pubmed-article:16224068pubmed:paginatione88-96lld:pubmed
pubmed-article:16224068pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:meshHeadingpubmed-meshheading:16224068...lld:pubmed
pubmed-article:16224068pubmed:year2005lld:pubmed
pubmed-article:16224068pubmed:articleTitleTranscriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II.lld:pubmed
pubmed-article:16224068pubmed:affiliationDivision of Endocrinology, Diabetes, and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.lld:pubmed
pubmed-article:16224068pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16224068pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:16224068pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16224068pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16224068lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16224068lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16224068lld:pubmed